Date:3/2/2010

PITTSBURGH, March 2 /PRNewswire-FirstCall/ -- Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Pharmaceuticals Inc. received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Ursodiol Capsules USP, 300 mg, the generic version of Watson's gastrointestinal agent Actigall® Capsules.

Ursodiol Capsules had U.S. sales of approximately $30 million for the 12 months ending Dec. 31, 2009 according to IMS Health. Mylan's version is available for immediate shipment.

Currently, Mylan has 142 ANDAs pending U.S. Food and Drug Administration appro
'/>"/>

SOURCE Mylan Inc. Copyright©2010 PR Newswire. All rights reserved

0 GOOD

Page: 1 2
Related medicine technology :

1. Mylan Awarded NABP-VAWD Accreditation for Its Primary North American Distribution Facility
2. Mylan Confirms First-to-File Patent Challenge Relating to Caduet(R)
3. Mylan Receives Approval for Generic Version of GoLytely(R)
4. Mylan Declares Quarterly Preferred Stock Dividend
5. Mylan Pre-Pays All Scheduled 2011 Term-Loan Borrowings
6. Mylan Confirms First-to-File Patent Challenge Relating to Vytorin(R) Cholesterol Medication
7. Mylan Receives Tentative FDA Approval Under PEPFAR for Matrix Laboratories New Drug Application (NDA) for Efavirenz Tablets
8. Mylan Added to NASDAQ-100 Index
9. Mylan Receives Approval for Generic Version of Antiepileptic Keppra(R) 1000 mg
10. Mylan Announces Settlement Agreement Related to Antidepressant Effexor XR(R)
11. Mylans President of Europe, Middle East and Africa Elected President of European Generic Medicines Association